Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 72 entries
Sorted by: Best Match Show Resources per page
Affective Correlates of Psychosis in Parkinson's Disease.

Movement disorders clinical practice

Factor SA, Scullin MK, Freeman A, Bliwise DL, McDonald WM, Goldstein FC.
PMID: 28944257
Mov Disord Clin Pract. 2017 Mar-Apr;4(2):225-230. doi: 10.1002/mdc3.12381. Epub 2016 Jun 16.

OBJECTIVE: To examine the nature of the association between affective disorders and psychosis in Parkinson's disease (PD).BACKGROUND: In PD, psychosis and affective disorders are common and independently impact quality of life and mortality. Both depression and psychosis are correlated...

Cite
Factor SA, Scullin MK, Freeman A, et al. Affective Correlates of Psychosis in Parkinson's Disease. Mov Disord Clin Pract. 2016;4(2):225-230doi: 10.1002/mdc3.12381.
Factor, S. A., Scullin, M. K., Freeman, A., Bliwise, D. L., McDonald, W. M., & Goldstein, F. C. (2017). Affective Correlates of Psychosis in Parkinson's Disease. Movement disorders clinical practice, 4(2), 225-230. https://doi.org/10.1002/mdc3.12381
Factor, Stewart A, et al. "Affective Correlates of Psychosis in Parkinson's Disease." Movement disorders clinical practice vol. 4,2 (2017): 225-230. doi: https://doi.org/10.1002/mdc3.12381
Factor SA, Scullin MK, Freeman A, Bliwise DL, McDonald WM, Goldstein FC. Affective Correlates of Psychosis in Parkinson's Disease. Mov Disord Clin Pract. 2017 Mar-Apr;4(2):225-230. doi: 10.1002/mdc3.12381. Epub 2016 Jun 16. PMID: 28944257; PMCID: PMC5608273.
Copy Download .nbib Format: NLM
A review of the role of anticoagulation in the treatment of peripheral arterial disease.

The International journal of angiology : official publication of the International College of Angiology, Inc

Whayne TF.
PMID: 24293975
Int J Angiol. 2012 Dec;21(4):187-94. doi: 10.1055/s-0032-1330232.

Peripheral arterial disease (PAD) is a major medical/surgical problem associated with high risk for coronary heart disease (CHD). Anticoagulation plays a significant role in the management of the PAD patient. However, evidence-based medicine supports only select anticoagulants, mainly antiplatelet...

Cite
Whayne TF. A review of the role of anticoagulation in the treatment of peripheral arterial disease. Int J Angiol. 2012;21(4):187-94doi: 10.1055/s-0032-1330232.
Whayne, T. F. (2012). A review of the role of anticoagulation in the treatment of peripheral arterial disease. The International journal of angiology : official publication of the International College of Angiology, Inc, 21(4), 187-94. https://doi.org/10.1055/s-0032-1330232
Whayne, Thomas F. "A review of the role of anticoagulation in the treatment of peripheral arterial disease." The International journal of angiology : official publication of the International College of Angiology, Inc vol. 21,4 (2012): 187-94. doi: https://doi.org/10.1055/s-0032-1330232
Whayne TF. A review of the role of anticoagulation in the treatment of peripheral arterial disease. Int J Angiol. 2012 Dec;21(4):187-94. doi: 10.1055/s-0032-1330232. PMID: 24293975; PMCID: PMC3578611.
Copy Download .nbib Format: NLM
Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness.

Parkinsonism & related disorders

Hauser RA, Zesiewicz TA, Factor SA, Guttman M, Weiner WJ.
PMID: 18591048
Parkinsonism Relat Disord. 1997 Jan;3(1):1-6. doi: 10.1016/s1353-8020(96)00042-9.

Clinical trials designed to evaluate the efficacy of new anti-parkinsonian agents often employ an 'add-on' protocol in which patients with motor fluctuations on levodopa are randomized to receive active medication or placebo. Levodopa doses may not be increased, but...

Cite
Hauser RA, Zesiewicz TA, Factor SA, et al. Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness. Parkinsonism Relat Disord. 1997;3(1):1-6doi: 10.1016/s1353-8020(96)00042-9.
Hauser, R. A., Zesiewicz, T. A., Factor, S. A., Guttman, M., & Weiner, W. J. (1997). Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness. Parkinsonism & related disorders, 3(1), 1-6. https://doi.org/10.1016/s1353-8020(96)00042-9
Hauser, R A, et al. "Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness." Parkinsonism & related disorders vol. 3,1 (1997): 1-6. doi: https://doi.org/10.1016/s1353-8020(96)00042-9
Hauser RA, Zesiewicz TA, Factor SA, Guttman M, Weiner WJ. Clinical trials of add-on medications in Parkinson's disease: Efficacy versus usefulness. Parkinsonism Relat Disord. 1997 Jan;3(1):1-6. doi: 10.1016/s1353-8020(96)00042-9. PMID: 18591048.
Copy Download .nbib Format: NLM
The new oral anticoagulants.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation

Verheugt FW.
PMID: 20657677
Neth Heart J. 2010 Jun;18(6):314-8. doi: 10.1007/BF03091782.

In patients with nonvalvular atrial fibrillation oral anticoagulation with the vitamin K antagonists acenocoumarol, phenprocoumon and warfarin reduces the risk of stroke by more than 60%, whereas single or double antiplatelet therapy is much less effective and sometimes associated...

Cite
Verheugt FW. The new oral anticoagulants. Neth Heart J. 2010;18(6):314-8doi: 10.1007/BF03091782.
Verheugt, F. W. (2010). The new oral anticoagulants. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 18(6), 314-8. https://doi.org/10.1007/BF03091782
Verheugt, F W A. "The new oral anticoagulants." Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation vol. 18,6 (2010): 314-8. doi: https://doi.org/10.1007/BF03091782
Verheugt FW. The new oral anticoagulants. Neth Heart J. 2010 Jun;18(6):314-8. doi: 10.1007/BF03091782. PMID: 20657677; PMCID: PMC2881348.
Copy Download .nbib Format: NLM
Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion

Agarwal MB, Verma S, Mahapatra M, Tripathi AK, Bhave A, Deshpande A, Vora A, Dalal JJ, Shah AB, Bichu S.
PMID: 23997448
Indian J Hematol Blood Transfus. 2012 Sep;28(3):129-43. doi: 10.1007/s12288-012-0167-6. Epub 2012 Jul 28.

With the evaluation and approval of newer oral anticoagulants such as the factor IIa inhibitor, dabigatran etexilate and the factor Xa inhibitors, rivaroxaban and apixaban, strategies for stroke prevention in atrial fibrillation need a thorough re-evaluation of current options....

Cite
Agarwal MB, Verma S, Mahapatra M, et al. Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants. Indian J Hematol Blood Transfus. 2012;28(3):129-43doi: 10.1007/s12288-012-0167-6.
Agarwal, M. B., Verma, S., Mahapatra, M., Tripathi, A. K., Bhave, A., Deshpande, A., Vora, A., Dalal, J. J., Shah, A. B., & Bichu, S. (2012). Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion, 28(3), 129-43. https://doi.org/10.1007/s12288-012-0167-6
Agarwal, M B, et al. "Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants." Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion vol. 28,3 (2012): 129-43. doi: https://doi.org/10.1007/s12288-012-0167-6
Agarwal MB, Verma S, Mahapatra M, Tripathi AK, Bhave A, Deshpande A, Vora A, Dalal JJ, Shah AB, Bichu S. Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants. Indian J Hematol Blood Transfus. 2012 Sep;28(3):129-43. doi: 10.1007/s12288-012-0167-6. Epub 2012 Jul 28. PMID: 23997448; PMCID: PMC3422392.
Copy Download .nbib Format: NLM
Plasticity-related gene 3 (.

Neurology. Genetics

Wallen ZD, Chen H, Hill-Burns EM, Factor SA, Zabetian CP, Payami H.
PMID: 30338293
Neurol Genet. 2018 Oct 05;4(5):e271. doi: 10.1212/NXG.0000000000000271. eCollection 2018 Oct.

OBJECTIVE: To identify modifiers of age at diagnosis of Parkinson disease (PD).METHODS: Genome-wide association study (GWAS) included 1,950 individuals with PD from the NeuroGenetics Research Consortium (NGRC) study. Replication was conducted in the Parkinson's, Genes and Environment study, including...

Cite
Wallen ZD, Chen H, Hill-Burns EM, et al. Plasticity-related gene 3 (. Neurol Genet. 2018;4(5):e271doi: 10.1212/NXG.0000000000000271.
Wallen, Z. D., Chen, H., Hill-Burns, E. M., Factor, S. A., Zabetian, C. P., & Payami, H. (2018). Plasticity-related gene 3 (. Neurology. Genetics, 4(5), e271. https://doi.org/10.1212/NXG.0000000000000271
Wallen, Zachary D, et al. "Plasticity-related gene 3 (." Neurology. Genetics vol. 4,5 (2018): e271. doi: https://doi.org/10.1212/NXG.0000000000000271
Wallen ZD, Chen H, Hill-Burns EM, Factor SA, Zabetian CP, Payami H. Plasticity-related gene 3 (. Neurol Genet. 2018 Oct 05;4(5):e271. doi: 10.1212/NXG.0000000000000271. eCollection 2018 Oct. PMID: 30338293; PMCID: PMC6186025.
Copy Download .nbib Format: NLM
LRRK2 levels in immune cells are increased in Parkinson's disease.

NPJ Parkinson's disease

Cook DA, Kannarkat GT, Cintron AF, Butkovich LM, Fraser KB, Chang J, Grigoryan N, Factor SA, West AB, Boss JM, Tansey MG.
PMID: 28649611
NPJ Parkinsons Dis. 2017 Mar 28;3:11. doi: 10.1038/s41531-017-0010-8. eCollection 2017.

Mutations associated with leucine-rich repeat kinase 2 are the most common known cause of Parkinson's disease. The known expression of leucine-rich repeat kinase 2 in immune cells and its negative regulatory function of nuclear factor of activated T cells...

Cite
Cook DA, Kannarkat GT, Cintron AF, et al. LRRK2 levels in immune cells are increased in Parkinson's disease. NPJ Parkinsons Dis. 2017;3:11doi: 10.1038/s41531-017-0010-8.
Cook, D. A., Kannarkat, G. T., Cintron, A. F., Butkovich, L. M., Fraser, K. B., Chang, J., Grigoryan, N., Factor, S. A., West, A. B., Boss, J. M., & Tansey, M. G. (2017). LRRK2 levels in immune cells are increased in Parkinson's disease. NPJ Parkinson's disease, 311. https://doi.org/10.1038/s41531-017-0010-8
Cook, D A, et al. "LRRK2 levels in immune cells are increased in Parkinson's disease." NPJ Parkinson's disease vol. 3 (2017): 11. doi: https://doi.org/10.1038/s41531-017-0010-8
Cook DA, Kannarkat GT, Cintron AF, Butkovich LM, Fraser KB, Chang J, Grigoryan N, Factor SA, West AB, Boss JM, Tansey MG. LRRK2 levels in immune cells are increased in Parkinson's disease. NPJ Parkinsons Dis. 2017 Mar 28;3:11. doi: 10.1038/s41531-017-0010-8. eCollection 2017. PMID: 28649611; PMCID: PMC5459798.
Copy Download .nbib Format: NLM
Lurasidone-Induced Tardive Syndrome.

Movement disorders clinical practice

Tripathi R, Reich SG, Scorr L, Guardiani E, Factor SA.
PMID: 31538095
Mov Disord Clin Pract. 2019 Jul 24;6(7):601-604. doi: 10.1002/mdc3.12812. eCollection 2019 Sep.

INTRODUCTION: Tardive syndrome (TS) is an often irreversible movement disorder caused by dopamine receptor-blocking agents (DRBAs). Although TS are well recognized to occur with typical antipsychotics, less well appreciated is that atypical antipsychotics also carry a risk of TS.METHODS:...

Cite
Tripathi R, Reich SG, Scorr L, et al. Lurasidone-Induced Tardive Syndrome. Mov Disord Clin Pract. 2019;6(7):601-604doi: 10.1002/mdc3.12812.
Tripathi, R., Reich, S. G., Scorr, L., Guardiani, E., & Factor, S. A. (2019). Lurasidone-Induced Tardive Syndrome. Movement disorders clinical practice, 6(7), 601-604. https://doi.org/10.1002/mdc3.12812
Tripathi, Richa, et al. "Lurasidone-Induced Tardive Syndrome." Movement disorders clinical practice vol. 6,7 (2019): 601-604. doi: https://doi.org/10.1002/mdc3.12812
Tripathi R, Reich SG, Scorr L, Guardiani E, Factor SA. Lurasidone-Induced Tardive Syndrome. Mov Disord Clin Pract. 2019 Jul 24;6(7):601-604. doi: 10.1002/mdc3.12812. eCollection 2019 Sep. PMID: 31538095; PMCID: PMC6749798.
Copy Download .nbib Format: NLM
Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society

Lewis SJG, Factor SA, Giladi N, Hallett M, Nieuwboer A, Nutt JG, Przedborski S, Papa SM.
PMID: 34939228
Mov Disord. 2021 Dec 22; doi: 10.1002/mds.28837. Epub 2021 Dec 22.

No abstract available.

Cite
Lewis SJG, Factor SA, Giladi N, et al. Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease. Mov Disord. 2021;doi: 10.1002/mds.28837.
Lewis, S. J. G., Factor, S. A., Giladi, N., Hallett, M., Nieuwboer, A., Nutt, J. G., Przedborski, S., Papa, S. M. (2021). Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society, . https://doi.org/10.1002/mds.28837
Lewis, Simon J G, et al. "Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease." Movement disorders : official journal of the Movement Disorder Society vol. (2021). doi: https://doi.org/10.1002/mds.28837
Lewis SJG, Factor SA, Giladi N, Hallett M, Nieuwboer A, Nutt JG, Przedborski S, Papa SM. Addressing the Challenges of Clinical Research for Freezing of Gait in Parkinson's Disease. Mov Disord. 2021 Dec 22; doi: 10.1002/mds.28837. Epub 2021 Dec 22. PMID: 34939228.
Copy Download .nbib Format: NLM
Cerebrospinal fluid biomarkers in Parkinson's disease with freezing of gait: an exploratory analysis.

NPJ Parkinson's disease

Hatcher-Martin JM, McKay JL, Pybus AF, Sommerfeld B, Howell JC, Goldstein FC, Wood L, Hu WT, Factor SA.
PMID: 34845234
NPJ Parkinsons Dis. 2021 Nov 29;7(1):105. doi: 10.1038/s41531-021-00247-x.

We explore the association between three Alzheimer's disease-related and ten inflammation-related CSF markers and freezing of gait (FOG) in patients with Parkinson's disease (PD). The study population includes PD patients with FOG (PD-FOG, N = 12), without FOG (PD-NoFOG,...

Cite
Hatcher-Martin JM, McKay JL, Pybus AF, et al. Cerebrospinal fluid biomarkers in Parkinson's disease with freezing of gait: an exploratory analysis. NPJ Parkinsons Dis. 2021;7(1):105doi: 10.1038/s41531-021-00247-x.
Hatcher-Martin, J. M., McKay, J. L., Pybus, A. F., Sommerfeld, B., Howell, J. C., Goldstein, F. C., Wood, L., Hu, W. T., & Factor, S. A. (2021). Cerebrospinal fluid biomarkers in Parkinson's disease with freezing of gait: an exploratory analysis. NPJ Parkinson's disease, 7(1), 105. https://doi.org/10.1038/s41531-021-00247-x
Hatcher-Martin, J M, et al. "Cerebrospinal fluid biomarkers in Parkinson's disease with freezing of gait: an exploratory analysis." NPJ Parkinson's disease vol. 7,1 (2021): 105. doi: https://doi.org/10.1038/s41531-021-00247-x
Hatcher-Martin JM, McKay JL, Pybus AF, Sommerfeld B, Howell JC, Goldstein FC, Wood L, Hu WT, Factor SA. Cerebrospinal fluid biomarkers in Parkinson's disease with freezing of gait: an exploratory analysis. NPJ Parkinsons Dis. 2021 Nov 29;7(1):105. doi: 10.1038/s41531-021-00247-x. PMID: 34845234; PMCID: PMC8629994.
Copy Download .nbib Format: NLM
Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease.

Science advances

Higginbotham L, Ping L, Dammer EB, Duong DM, Zhou M, Gearing M, Hurst C, Glass JD, Factor SA, Johnson ECB, Hajjar I, Lah JJ, Levey AI, Seyfried NT.
PMID: 33087358
Sci Adv. 2020 Oct 21;6(43). doi: 10.1126/sciadv.aaz9360. Print 2020 Oct.

Alzheimer's disease (AD) lacks protein biomarkers reflective of its diverse underlying pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used integrative proteomics to identify cerebrospinal fluid (CSF) biomarkers representing a wide spectrum of AD pathophysiology. Multiplex mass spectrometry identified...

Cite
Higginbotham L, Ping L, Dammer EB, et al. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease. Sci Adv. 2020;6(43)doi: 10.1126/sciadv.aaz9360.
Higginbotham, L., Ping, L., Dammer, E. B., Duong, D. M., Zhou, M., Gearing, M., Hurst, C., Glass, J. D., Factor, S. A., Johnson, E. C. B., Hajjar, I., Lah, J. J., Levey, A. I., & Seyfried, N. T. (2020). Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease. Science advances, 6(43), . https://doi.org/10.1126/sciadv.aaz9360
Higginbotham, Lenora, et al. "Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease." Science advances vol. 6,43 (2020). doi: https://doi.org/10.1126/sciadv.aaz9360
Higginbotham L, Ping L, Dammer EB, Duong DM, Zhou M, Gearing M, Hurst C, Glass JD, Factor SA, Johnson ECB, Hajjar I, Lah JJ, Levey AI, Seyfried NT. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease. Sci Adv. 2020 Oct 21;6(43). doi: 10.1126/sciadv.aaz9360. Print 2020 Oct. PMID: 33087358; PMCID: PMC7577712.
Copy Download .nbib Format: NLM
Discussion of Research Priorities for Gait Disorders in Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society

Bohnen NI, Costa RM, Dauer WT, Factor SA, Giladi N, Hallett M, Lewis SJG, Nieuwboer A, Nutt JG, Takakusaki K, Kang UJ, Przedborski S, Papa SM.
PMID: 34939221
Mov Disord. 2021 Dec 22; doi: 10.1002/mds.28883. Epub 2021 Dec 22.

Gait and balance abnormalities develop commonly in Parkinson's disease and are among the motor symptoms most disabling and refractory to dopaminergic or other treatments, including deep brain stimulation. Efforts to develop effective therapies are challenged by limited understanding of...

Cite
Bohnen NI, Costa RM, Dauer WT, et al. Discussion of Research Priorities for Gait Disorders in Parkinson's Disease. Mov Disord. 2021;doi: 10.1002/mds.28883.
Bohnen, N. I., Costa, R. M., Dauer, W. T., Factor, S. A., Giladi, N., Hallett, M., Lewis, S. J. G., Nieuwboer, A., Nutt, J. G., Takakusaki, K., Kang, U. J., Przedborski, S., Papa, S. M. (2021). Discussion of Research Priorities for Gait Disorders in Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society, . https://doi.org/10.1002/mds.28883
Bohnen, Nicolaas I, et al. "Discussion of Research Priorities for Gait Disorders in Parkinson's Disease." Movement disorders : official journal of the Movement Disorder Society vol. (2021). doi: https://doi.org/10.1002/mds.28883
Bohnen NI, Costa RM, Dauer WT, Factor SA, Giladi N, Hallett M, Lewis SJG, Nieuwboer A, Nutt JG, Takakusaki K, Kang UJ, Przedborski S, Papa SM. Discussion of Research Priorities for Gait Disorders in Parkinson's Disease. Mov Disord. 2021 Dec 22; doi: 10.1002/mds.28883. Epub 2021 Dec 22. PMID: 34939221.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 72 entries